Antibody-drug conjugates (ADC) represent a new way to  treat cancer. ADC are comprised of an antibody, a linker, and a payload. Unlike  traditional chemotherapy, ADC are targeted to impair cancer cells, while sparing  healthy cells. In this course, we discuss how ADC were developed, and their  mechanism of action. We also review several different ADC therapies and the  differences between them. Come discover why ADC are of the fastest growing  cancer therapies and how they will affect our patients.

Over 700 attended our event and we received amazing feedback!

Feedback from anonymous survey:

• Extremely knowledgeable speaker and interesting topic.

• Amazing topic. It was great listening to details on the MOA of cancer treatments and how it can impact the eyes.

• Thank you for thinking outside the box with this topic, I love learning new things that can help me practice better

• Thank you so much. So many of my patients have cancer. This information is so good to know.

• Good course helps me understand some cancer treatments

• It was great learning about the MOA of cancer treatments and how they can affect the eyes

• Good speaker and very understandable on a difficult subject

• This was an excellent presentation on a new and novel therapy.

• Fascinating topic. Thank you for opening my eyes to other aspects of healthcare.

• Dr. Borghaei is an excellent speaker. What a great lecture!

• Excellent Lecture- Very informative and interesting! Thank You Very Much!

• Excellent education and presentation, thank you!

• Always great to learn something new!

• I enjoyed learning about the newer modes of cancer treatment currently being tested. It's interesting to see how it affects the eyes.

Speaker: Dr. Hossein Borghaei

Thank you to ImmunoGen for supporting this event with unrestricted educational grant.

This event is COPE approved for 1 hour of ce credit.